Advanced Solid Tumor
Conditions
Keywords
Cancer, Immunotherapy, Vaccine, Intradermal, gp96, OX40, Combination Therapy, Co-stimulation, Heat Biologics
Brief summary
This is a phase 1 open-label, single center, dose escalation study to determine a safe and effective maximum tolerated dose of HS-130 in combination with viagenpumatucel-L (HS-110) for adult subjects with advanced solid tumors who are refractory to Standard of Care.
Detailed description
This is an open-label, non-controlled, first-in-human Phase I study of HS-130 and HS-110 in patients with advanced solid tumors refractory to, or ineligible for, Standard of Care. Seven dose levels will be explored in escalating doses. For each dose level, patients will receive combination HS-130 and HS-110 via intradermal injections once every 14 days. The Dose Limiting Toxicity (DLT) window of observation will include the first 28 days of treatment. In the absence of progressive disease or unacceptable toxicity, patients will continue to receive combination treatment every two weeks until disease progression, death, patient's withdrawal of consent, Investigator decision to discontinue treatment, or intolerable toxicity, whichever occurs first.
Interventions
BIOLOGICALHS-110 (viagenpumatucel-L)
Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
BIOLOGICALHS-130
Vaccine derived from irradiated human lung cancer cells expressing the co-stimulatory fusion protein OX40L-Ig
Sponsors
Heat Biologics
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with metastatic or advanced, unresectable solid tumor who have progressed, or recurred following standard-of-care (SOC) therapies or are ineligible for safe and effective SOC therapies and for whom, in the opinion of the Investigator, experimental therapy with HS-130/HS-110 may be beneficial. 2. Patients should have lesions that are safely accessible for biopsy and be willing to provide pre-treatment and on-treatment tissue biopsy. Fine-needle aspiration biopsy is not acceptable. Archival tumor tissue will be accepted in lieu of fresh biopsy at screening if sample was collected within 6-months from Cycle 1 Day 1, and the local pathologist confirms that an adequate amount of tissue/tumor cells exist to allow completion of all testing as outlined in the specimen collection manual. 3. Age ≥ 18 years. 4. Have an acceptable organ function: * Albumin ≥ 2.5 g/dL. * Total Bilirubin \< 3.0 × upper limit of normal (ULN) unless patient has Gilbert's syndrome. * Alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 3.0 × ULN or ≤ 5 × ULN in the case of liver metastases. * Calculated or measured creatinine clearance \> 35 mL/minute per the Cockcroft-Gault formula. * Absolute neutrophil count ≥ 1,500/mm3. * Hemoglobin ≥ 9 g/dL. * Platelet count ≥ 100,000/mm3. 5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 6. Life expectancy of at least three months. 7. Patients, both females and males, of childbearing/reproductive potential must agree to use adequate contraception while included in the trial and for six months after the last treatment with HS-130 and/or HS-110. 8. Patients must be willing and have the capacity to sign the informed consent form.
Exclusion criteria
1. Have clinically significant cardiac disease, including: * Onset of unstable angina within 6 months of signing the Informed Consent Form (ICF). * Acute myocardial infarction within 6 months of the signing the ICF. * Known congestive heart failure (Grade III or IV as classified by the New York Heart Association); and/ or a known decreased cardiac ejection fraction (LVEF) of \< 45%. * Uncontrolled hypertension defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥ 100 mmHg, despite optimal medical management. 2. Known or clinically suspected leptomeningeal disease. Stable, previously treated metastases in the brain or spinal cord, are allowed as long as these are considered stable (by CT or MRI), and not requiring systemic corticosteroids. 3. History of ≥ grade 3 allergic reactions as well as known or suspected allergy or intolerance to any agent given in the course of this trial, live cell therapies, or live vaccines. 4. History of suspected cytokine release syndrome (CRS). 5. Known immunodeficiency disorders (testing not required). 6. Ongoing or current autoimmune disease. Permanent but stable and manageable immune related adverse events (irAE) from prior therapies are permissible, if prednisone equivalent corticosteroid use does not exceed 10 mg/day. 7. Any other condition requiring concurrent systemic immunosuppressive therapy (other than allowable exceptions which do not exceed 10mg/day of prednisone/corticosteroid use). 8. Major surgery (requiring general anesthesia or inpatient hospitalization) within four weeks before first IMP administration. 9. Any ongoing anticancer therapy including; small molecules, immunotherapy, chemotherapy, monoclonal antibodies or any other experimental drug. Prior therapy must be stopped within four weeks before first infusion in the study, or 5 half-lives, or twice the duration of the biological effect of the investigational product (whichever is shortest). Adjuvant anti-hormonal treatment(s) for previously treated breast cancer or prostate cancer are allowed. Bisphosphonates are allowed, Denosumab and other RANK ligand inhibitors are prohibited. 10. Known current malignancy other than inclusion diagnosis. Prior curable cancer with complete remission for \>2 years is allowed. 11. Any other ongoing significant, uncontrolled medical condition as per Investigator discretion. 12. Received a live vaccine within 30 days prior to first dose of study drug. 13. Clinically significant active viral, bacterial or fungal infection requiring: 1. Intravenous treatment with antimicrobial therapy completed less than two weeks prior to first dose, or 2. Oral treatment with antimicrobial therapy completed less than one week prior to first dose. Prophylactic treatment with antibiotics (e.g. for dental extractions) is allowed. 14. Known positive serology for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C (except in cases of immunity after cured infection). Testing not required. 15. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the trial or evaluation of the trial result in the opinion of the Investigator. 16. Women who are pregnant or breast feeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose Limiting Toxicity | 1 month | Number of Patients with Dose Limiting Toxicity (DLT) |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1: HS-130 (150 ng- 600 ng) + HS-110 (150 ng - 300 ng) (Viagenpumatucel-L) Patients will receive a combination of intradermal HS-130 and HS-110 once every 14 days. The dose levels will be determined by the starting dose and the escalation steps outlined in the protocol.
HS-110 (viagenpumatucel-L): Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
HS-130: Vaccine derived from irradiated human lung cancer cells expressing the co-stimulatory fusion protein OX40L-Ig | 4 |
| Cohort 2: HS-130 (600 ng) + HS-110 (600 ng) (Viagenpumatucel-L) Patients will receive a combination of intradermal HS-130 and HS-110 once every 14 days. The dose levels will be determined by the starting dose and the escalation steps outlined in the protocol.
HS-110 (viagenpumatucel-L): Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
HS-130: Vaccine derived from irradiated human lung cancer cells expressing the co-stimulatory fusion protein OX40L-Ig | 6 |
| Cohort 3: HS-130 (1200 ng) + HS-110 (600 ng) (Viagenpumatucel-L) Patients will receive a combination of intradermal HS-130 and HS-110 once every 14 days. The dose levels will be determined by the starting dose and the escalation steps outlined in the protocol.
HS-110 (viagenpumatucel-L): Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
HS-130: Vaccine derived from irradiated human lung cancer cells expressing the co-stimulatory fusion protein OX40L-Ig | 3 |
| Cohort 4: HS-130 (1200 ng) + HS-110 (1200 ng) (Viagenpumatucel-L) Patients will receive a combination of intradermal HS-130 and HS-110 once every 14 days. The dose levels will be determined by the starting dose and the escalation steps outlined in the protocol.
HS-110 (viagenpumatucel-L): Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
HS-130: Vaccine derived from irradiated human lung cancer cells expressing the co-stimulatory fusion protein OX40L-Ig | 2 |
| Total | 15 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Death | 4 | 6 | 3 | 1 |
| Overall Study | Withdrawal by Subject | 0 | 0 | 0 | 1 |
Baseline characteristics
| Characteristic | Cohort 1: HS-130 (150 ng- 600 ng) + HS-110 (150 ng - 300 ng) (Viagenpumatucel-L) | Cohort 2: HS-130 (600 ng) + HS-110 (600 ng) (Viagenpumatucel-L) | Cohort 3: HS-130 (1200 ng) + HS-110 (600 ng) (Viagenpumatucel-L) | Cohort 4: HS-130 (1200 ng) + HS-110 (1200 ng) (Viagenpumatucel-L) | Total |
|---|---|---|---|---|---|
| Age, Continuous | 73.5 years STANDARD_DEVIATION 3.51 | 49.8 years STANDARD_DEVIATION 7.52 | 62.3 years STANDARD_DEVIATION 7.02 | 69.0 years STANDARD_DEVIATION 9.9 | 61.2 years STANDARD_DEVIATION 12.02 |
| Race/Ethnicity, Customized Race Unknown | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Race White | 4 Participants | 5 Participants | 3 Participants | 2 Participants | 14 Participants |
| Region of Enrollment United States | 4 participants | 6 participants | 3 participants | 2 participants | 15 participants |
| Sex: Female, Male Female | 3 Participants | 2 Participants | 3 Participants | 0 Participants | 8 Participants |
| Sex: Female, Male Male | 1 Participants | 4 Participants | 0 Participants | 2 Participants | 7 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 4 / 4 | 6 / 6 | 3 / 3 | 1 / 2 |
| other Total, other adverse events | 4 / 4 | 6 / 6 | 3 / 3 | 2 / 2 |
| serious Total, serious adverse events | 0 / 4 | 1 / 6 | 1 / 3 | 1 / 2 |
Outcome results
Primary
Dose Limiting Toxicity
Number of Patients with Dose Limiting Toxicity (DLT)
Time frame: 1 month
Population: The safety population includes all patients who received at least one dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1: HS-130 (150 ng- 600 ng) + HS-110 (150 ng - 300 ng) (Viagenpumatucel-L) | Dose Limiting Toxicity | 0 Participants |
| Cohort 2: HS-130 (600 ng) + HS-110 (600 ng) (Viagenpumatucel-L) | Dose Limiting Toxicity | 0 Participants |
| Cohort 3: HS-130 (1200 ng) + HS-110 (600 ng) (Viagenpumatucel-L) | Dose Limiting Toxicity | 0 Participants |
| Cohort 4: HS-130 (1200 ng) + HS-110 (1200 ng) (Viagenpumatucel-L) | Dose Limiting Toxicity | 0 Participants |